Medicxi launches a diabetes upstart with $11M; Arrowhead partners on hep B; Immunotherapy startup gains $12.2M round
The Medicxi venture group has committed up to 10 million euros to back a spinout focusing on diabetes and metabolics. The upstart Kymo Therapeutics …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
